[O-06] Oral Session 06

[O-06-4] Rozanolixizumab in muscle-specific kinase antibody-positive myasthenia gravis: Phase 3 outcomes [Encore Presentation]

Kimiaki Utsugisawa^1,15, Henry Kaminski^2,15, Artur Druzdz^3,15, Julian Grosskreutz^4,15, Ali A Habib^5,15, Renato Mantegazza^6,15, Sabrina Sacconi^7,15, Takamichi Sugimoto^8,15, Shigeaki Suzuki^9,15, Masanori Takahashi^10,15, John Vissing^11,15, Tuan Vu^12,15, Marion Boehnlein¹³, Bernhard Greve¹³, Vera Bril^14,15 (1.Department of Neurology, Hanamaki General Hospital, Japan, 2.Department of Neurology & Rehabilitation Medicine, George Washington University, USA, 3.Department of Neurology, Municipal Hospital Poznan, Poland, 4.Precision Neurology, Department of Neurology, University of Lubeck, Germany, 5.Department of Neurology, University of California, USA, 6.Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologico Carlo Besta, Italy, 7.Universite Cote d'Azur, Peripheral Nervous System and Muscle Department, Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, France, 8.Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan, 9.Department of Neurology, Keio University School of Medicine, Japan, 10.Department of Clinical Laboratory and Biomedical Sciences, Osaka University Graduate School of Medicine, Japan, 11.Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Denmark, 12.Department of Neurology, University of South Florida Morsani College of Medicine, USA, 13.UCB Pharma, Germany, 14.University Health Network, Canada, 15.MycarinG Study investigators, Other country)